Press releases

Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment

09 October 2019

Read more - Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment Read more

Many Canadian Adults Acknowledge the Importance of Immunization Yet Are Not Getting Vaccinated

04 June 2019

Read more - Many Canadian Adults Acknowledge the Importance of Immunization Yet Are Not Getting Vaccinated Read more

Local employee selected for charity mountain climb

26 March 2019

Read more - Local employee selected for charity mountain climb Read more

New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration

20 February 2019

Read more - New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration Read more

GSK statement on vaccine shortages

09 November 2018

Read more - GSK statement on vaccine shortages Read more

GSK’s Mississauga manufacturing operations undergoes $36 M modernization; Site to produce leading topical pain reliever, VOLTAREN

13 September 2018

Read more - GSK’s Mississauga manufacturing operations undergoes $36 M modernization; Site to produce leading topical pain reliever, VOLTAREN Read more

National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up

18 June 2018

Read more - National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up Read more

GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec

31 May 2018

Read more - GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec Read more

Quebec’s Committee on Immunization (CIQ) recommends preferential use of SHINGRIX for the prevention of shingles in adults aged 50 and up

23 April 2018

Read more - Quebec’s Committee on Immunization (CIQ) recommends preferential use of SHINGRIX for the prevention of shingles in adults aged 50 and up Read more

TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD

05 April 2018

Read more - TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD Read more

What we do

How we do it

Policies, codes and standards

Our prescription medicines and vaccines

Our consumer healthcare products

ViiV Healthcare

Stiefel - Dermatology

Search jobs and apply

Working for GSK

Areas of opportunity

Sharing our research

Open innovation

Trials in people

Access to healthcare

Operating responsibly

Our people

Environmental sustainability

Responsibility reports and additional data

Two new options for self-administration of NUCALA now approved in Canada, making it the first anti-IL5 biologic to offer patients with severe eosinophilic asthma a choice of how and where to receive treatment

Many Canadian Adults Acknowledge the Importance of Immunization Yet Are Not Getting Vaccinated

Local employee selected for charity mountain climb

New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration

GSK statement on vaccine shortages

GSK’s Mississauga manufacturing operations undergoes $36 M modernization; Site to produce leading topical pain reliever, VOLTAREN

National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up

GSK and NEOMED call for proposals for innovative early stage human therapeutic projects in Quebec

Quebec’s Committee on Immunization (CIQ) recommends preferential use of SHINGRIX for the prevention of shingles in adults aged 50 and up

TRELEGY ELLIPTA approved in Canada as the first single inhaler triple therapy for the treatment of appropriate patients with COPD